Status:

COMPLETED

CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly

Lead Sponsor:

Peking Union Medical College Hospital

Conditions:

Aplastic Anemia

Eligibility:

All Genders

60+ years

Phase:

PHASE4

Brief Summary

This is a multicenter, prospective, randonmized study. Our previous retrospective study showed that for SAA patients who were intolerant to ATG, CsA+ eltrombopag (EPAG) had similar efficacy to CsA+ATG...

Detailed Description

Aplastic anemia (AA) can be divided into severe AA (SAA) and non-severe AA (NSAA), according to the severity of the disease. For SAA patients with o condition of hematopoietic stem cell transplantatio...

Eligibility Criteria

Inclusion

  • Patients with newly diagnosed severe aplastic anemia, aged greater than 60 years.
  • Patients met the diagnostic criteria of severe aplastic anemia (SAA).
  • Complete all screening assessments as outlined in the test protocol.
  • Without or with no more than 1 month treatment of ciclosporine, tacrolimus, glucocortocoid, or TPO-RAs.
  • Agree to sign the informed consent form.

Exclusion

  • Known diagnosis of congenital hematopoietic failure disorders (e.g. Fanconi anemia) and other causes of cytopenia.
  • Patients with uncontrolled bleeding and/or infection despite standard treatment.
  • Patients with previous history of hematopoietic stem cell transplantation.
  • Patients with previous history of thrombosis in 1 year.
  • Patients with concurrent malignancy.
  • Those who are considered unsuitable for enrollment by the investigator.
  • Abnormal renal function: creatinine \> 1.2 normal upper limit, albumin \< 0.9 normal lower limit, or CLcr \< 30 ml/min.
  • Abnormal liver function: transaminase \> 2.5 normal upper limit, or tota bilirubin \> 2.5 normal upper limit.
  • Patients with severe heart, liver or renal disease.

Key Trial Info

Start Date :

September 15 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 27 2025

Estimated Enrollment :

86 Patients enrolled

Trial Details

Trial ID

NCT05996393

Start Date

September 15 2023

End Date

February 27 2025

Last Update

April 30 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Peking union medical college hospital

Beijing, China